Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Akebia Therapeutics, Keryx Biopharmaceuticals Merge

Akebia Therapeutics announced a merger agreement with Keryx Biopharmaceuticals to create a company expected to be a leader in the development of renal disease therapies.

Read More »

Sesen Bio Shares Plunge Despite Reporting Positive Interim Phase III Results

Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.

Read More »

Akorn sues Fresenius over deal termination

U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

Read More »

Merck to Acquire Viralytics for $394 Million

Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.

Read More »

PDL BioPharma Gives Up On Acquiring Neos

Nevada-based PDL BioPharma will no longer pursue a proposed acquisition of Neos Therapeutics. PDL made three failed attempts to acquire Texas-based Neos.

Read More »

Teva Surges After Warren Buffett’s Berkshire Reports $358 Million Stake

Shares of Teva Pharmaceutical were up following news reports that billionaire investor Warren Buffett took a stake in the company.

Read More »

Gilead fourth-quarter hepatitis C drug sales plummet, sees further slowdown

Gilead Sciences Inc. said fourth-quarter 2017 sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for 2018.

Read More »

Allergan’s migraine drug succeeds in key study

Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.

Read More »

AstraZeneca Posts Disappointing 2017 Financials

AstraZeneca saw revenues and product sales fall over the course of 2017. Total revenues declined 2 percent to $22.46 billion and product sales fell 5 percent to $20.15 billion.

Read More »

Sanofi Acquires Ablynx for $4.85 Billion

One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom